Fresh Frozen Plasma (FFP) Dose Calculator
Enter patient weight and the prescribed dose in mL/kg to find the total FFP volume required and how many standard units to order. The calculator also estimates the expected rise in coagulation factor activity and flags when inputs fall outside the standard therapeutic dose range of 10-20 mL/kg.
What is fresh frozen plasma and when is it used?
Fresh frozen plasma (FFP) is the liquid component of whole blood that has been separated and frozen within 8 hours of collection. It contains all coagulation factors at approximately 1 IU/mL, fibrinogen (400-900 mg per unit), albumin, protein C, protein S, antithrombin, and tissue factor pathway inhibitor. FFP is indicated for patients who have a documented coagulation factor deficiency combined with either active bleeding or an imminent invasive procedure. The main clinical scenarios are: severe haemorrhage with dilutional coagulopathy (including massive transfusion protocols), warfarin reversal when vitamin K and prothrombin complex concentrates are unavailable or insufficient, thrombotic thrombocytopenic purpura (TTP) where it is used as both a replacement and exchange fluid, and rare congenital factor deficiencies where specific concentrates do not exist. FFP is not appropriate for simple volume expansion, as a protein supplement, or to reverse anticoagulation in the absence of bleeding.
How to calculate the FFP dose
The standard adult dose is 10-20 mL/kg of actual body weight, with 12-15 mL/kg being the most common starting order. The calculation is straightforward: multiply the patient weight in kilograms by the prescribed dose in mL/kg to get the total volume in mL, then divide by the volume of one unit and round up to the next whole unit. For example, a 70 kg patient receiving 15 mL/kg requires 70 x 15 = 1,050 mL, which is 1,050 / 250 = 4.2 units, so 5 standard pooled units would be ordered. Each 1 mL/kg of FFP raises coagulation factor activity by approximately 1%, so a 15 mL/kg dose is expected to raise levels by around 15%. The clinical target is usually a PT and aPTT below 1.5 times the upper limit of normal. Repeat dosing may be needed because coagulation factors have short half-lives and ongoing losses in actively bleeding patients can quickly consume transfused factors.
ABO compatibility and administration
Unlike red blood cell transfusions, FFP contains antibodies against A and B antigens rather than the antigens themselves. This means the plasma must be ABO-compatible with the recipient's red cells. Group AB plasma is the universal plasma type because it contains neither anti-A nor anti-B antibodies and can be given to any ABO group in an emergency. Group A plasma can go to group A or group O recipients; group B plasma to group B or group O recipients; group O plasma can only safely go to group O recipients. Rh type compatibility is not required for plasma. Each unit must be fully thawed before infusion, which takes 20-30 minutes in a 30-37 C water bath or 2-3 minutes in an FDA-cleared rapid thaw device. Once thawed, the unit should be infused as soon as possible - the standard infusion rate is approximately 30 minutes per unit, and no unit should infuse for longer than 4 hours. Thawed units stored at 1-6 C retain acceptable factor activity for 24 hours under most institutional policies, and some protocols extend this to 5-7 days for non-labile factor content.
Adverse effects and contraindications
The most serious adverse effect of FFP transfusion is transfusion-related acute lung injury (TRALI), which is the leading cause of transfusion-related death and presents as new acute hypoxia and bilateral pulmonary infiltrates within 6 hours of transfusion. Other immunological reactions include allergic reactions (mild urticaria in about 1% of transfusions; anaphylaxis in less than 1 per 100,000), febrile nonhemolytic reactions, and haemolytic reactions if ABO-incompatible plasma is given. Non-immunological complications include transfusion-associated circulatory overload (TACO), which is more likely with large-volume or rapid infusions in patients with cardiac or renal impairment, and citrate toxicity (causing hypocalcaemia), which is most relevant in neonates, patients with liver disease, and those receiving large-volume transfusions. Infectious transmission risks (HIV, hepatitis B, hepatitis C) are very low with modern screening but are not zero. FFP is absolutely contraindicated in patients with a documented hypersensitivity to plasma-derived products and in those with congenital IgA deficiency with known anti-IgA antibodies. It should be used with caution in patients with heart failure or pulmonary oedema.
FFP dosing and clinical reference
| Parameter | Value | Notes |
|---|---|---|
| Typical therapeutic dose | 10-20 mL/kg | Most common starting dose: 12-15 mL/kg |
| Standard pooled unit volume | 200-300 mL | 250 mL is the most common default |
| Apheresis unit volume | 400-600 mL | Single-donor; fewer exposures |
| Expected factor-level rise | ~1% per mL/kg | Approximate; patient plasma volume dependent |
| Coagulation factor content | ~1 IU/mL each | All coagulation factors present |
| Fibrinogen content per unit | 400-900 mg | Single 250 mL unit raises fibrinogen ~5-10 mg/dL |
| Target PT/aPTT | <1.5x normal | Common clinical endpoint for coagulopathy |
| Infusion time per unit | ~30 min (max 4 h) | Administer as soon as possible after thaw |
| Thaw time (water bath) | 20-30 min at 30-37 C | FDA-cleared devices: 2-3 min |
| ABO compatibility | Required | AB plasma is the universal plasma donor type |
| Storage (frozen) | -30 C or colder | Shelf life 12 months from collection |
| Post-thaw storage | 1-6 C | Use within 24 h; some protocols allow up to 5-7 days |
Standard clinical parameters for FFP transfusion in adults. Always follow institutional protocols.
Frequently asked questions
What is the standard FFP dose for an adult?
The standard dose is 10-20 mL/kg of actual body weight. Most clinicians start at 12-15 mL/kg. For a 70 kg adult, 15 mL/kg comes to 1,050 mL, which is approximately 4-5 standard pooled units of 250 mL each. The exact dose depends on the clinical indication, the severity of the coagulopathy, and the laboratory targets being used.
How many units of FFP are in 1,000 mL?
If you are using standard pooled units of 250 mL each, 1,000 mL equals exactly 4 units. With 200 mL units it is 5 units, and with 300 mL units it is approximately 3.3 units (so 4 units would be ordered to ensure the full dose is delivered). Apheresis-derived single-donor units of 500-600 mL mean that roughly 2 bags provide 1,000-1,200 mL.
Does FFP have to be ABO-compatible?
Yes. FFP contains antibodies to ABO blood group antigens, so it must be compatible with the recipient's red cell type. Group AB plasma is the universal plasma type because it has no anti-A or anti-B antibodies. In emergencies when the patient's blood group is unknown, AB plasma is used. Rh (D) compatibility is not required for plasma products.
How long does it take to thaw FFP?
Thawing in a 30-37 C water bath takes 20-30 minutes. FDA-cleared rapid thaw devices reduce this to 2-3 minutes. Because thawing takes time, clinicians planning to use FFP should order it early during active resuscitation. Once thawed, units should be administered as soon as possible and infused within 4 hours.
What is the difference between FFP and PF24 (plasma frozen within 24 hours)?
FFP is frozen within 8 hours of collection and retains optimal levels of all clotting factors, including the labile factors V and VIII. PF24 (plasma frozen within 24 hours of phlebotomy) has modestly lower levels of factor V and VIII but is equivalent for most clinical indications. Both products are used interchangeably in most transfusion medicine practice outside of situations where high factor VIII levels are specifically required.
Can FFP be used to reverse warfarin?
Yes, FFP can reverse warfarin by replacing the vitamin K-dependent clotting factors (II, VII, IX, X) that warfarin inhibits. However, prothrombin complex concentrates (PCCs) are preferred in most current guidelines because they deliver a more concentrated factor dose in a smaller volume, work faster, and carry a lower risk of volume overload. FFP remains an option when PCCs are unavailable or contraindicated.
What laboratory value do clinicians target when giving FFP?
The most commonly used target is a prothrombin time (PT) and activated partial thromboplastin time (aPTT) of less than 1.5 times the upper limit of normal. For patients undergoing massive transfusion, many centres use a fixed ratio protocol (for example 1:1:1 - red cells to plasma to platelets) rather than waiting for laboratory results, because results lag behind the clinical situation.